{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:04:38Z","timestamp":1783400678864,"version":"3.54.6"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ijantimicag.2020.106111","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T11:12:57Z","timestamp":1595675577000},"page":"106111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Assessment of the in vitro activity of ceftazidime\/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015\u20132017)"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-0434","authenticated-orcid":false,"given":"Gian Maria","family":"Rossolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-2567","authenticated-orcid":false,"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106111_bib0001","first-page":"301","article-title":"Update on the main MDR pathogens: prevalence and treatment options","volume":"25","author":"Esposito","year":"2017","journal-title":"Infez Med"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0002","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0003","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2020.106111_bib0004","article-title":"Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/cid\/ciy955","article-title":"The mortality burden of multidrug-resistant pathogens in India: a retrospective observational study","volume":"69","author":"Gandra","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0007","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0008","unstructured":"Allergan. Avycaz (ceftazidime\u2013avibactam) for injection, for intravenous use: prescribing information. Allergan; revised 01\/2018.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206494s004lbl.pdf. [accessed 20 May 2019]."},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0009","series-title":"Zavicefta: summary of product characteristics","author":"Pfizer","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0010","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1128\/AAC.02841-15","article-title":"Assessment of the in vitro activity of ceftazidime\u2013avibactam against multidrug-resistant Klebsiella spp. collected in the INFORM global surveillance study, 2012 to 2014","volume":"60","author":"Hackel","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0011","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","year":"2015"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0012","year":"2019","journal-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0013","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12941-017-0191-3","article-title":"Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae","volume":"16","author":"Xu","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0015","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1128\/AAC.00897-16","article-title":"Interaction of avibactam with class B metallo-\u03b2-lactamases","volume":"60","author":"Abboud","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106111_bib0016","doi-asserted-by":"crossref","first-page":"E934","DOI":"10.3390\/jcm8070934","article-title":"Treatment options for colistin resistant Klebsiella pneumoniae: present and future","volume":"8","author":"Petrosillo","year":"2019","journal-title":"J Clin Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:45Z","timestamp":1760377065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0924857920302946"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106111","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the in vitro activity of ceftazidime\/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015\u20132017)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106111"}}